Clinical Trial Update: Study Evaluating GAP-486 in Heart Rhythm [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GAP-486 for cardiac arrhythmias has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Arrhythmia

Drugs mentioned

• GAP-486

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Arrhythmia | Phase 2 | Status: TERMINATED